BioCentury
ARTICLE | Company News

Enumeral Biomedical, Pieris Pharmaceuticals deal

May 2, 2016 7:00 AM UTC

Enumeral granted Pieris exclusive, worldwide rights to IP related to its preclinical anti- PD-1 antibody program, ENUM 388D4, for development and commercialization of fusion proteins based on Pieris’ Anticalins platform to treat cancer. Enumeral will receive $250,000 up front for the initial license. Pieris may continue the license by paying Enumeral an additional $750,000 maintenance fee by May 31. If Pieris does not pay the maintenance fee, the license will terminate. If Pieris continues the license, it will receive a 12-month option to license Enumeral IP related to an additional antibody program against an undisclosed immuno-oncology target on the same terms and conditions as for the initial license. The antibody subject to the option will be selected by Pieris from a specified list of antibodies owned by Enumeral. ...